Residency · Residency · Endocrinology

Hypoparathyroidism and Hypocalcemia

Hypocalcemia - Differential Diagnosis

PTH-Dependent (Low PTH)

The PTH-dependent causes of hypocalcemia are those in which the parathyroid glands fail to produce adequate PTH in the setting of low calcium. Post-surgical hypoparathyroidism is the most common cause overall, accounting for approximately 75% of cases, and develops after thyroidectomy, parathyroidectomy, or radical neck dissection. In most cases (70-80%), the hypoparathyroidism is transient, reflecting temporary ischemia or stunning of the parathyroid glands, but it becomes permanent when it persists beyond 6 months.

Autoimmune hypoparathyroidism may occur in isolation or as part of autoimmune polyglandular syndrome type 1 (APS-1/APECED), which is caused by AIRE gene mutations and presents with the classic triad of hypoparathyroidism, adrenal insufficiency, and mucocutaneous candidiasis. Antibodies against the CaSR and against NALP5 have been identified in subsets of these patients. Infiltrative processes including hemochromatosis (iron deposition), Wilson disease (copper deposition), metastatic cancer, and granulomatous disease can progressively destroy parathyroid tissue. External beam radiation to the neck is a rare cause.

Genetic causes encompass several important conditions. DiGeorge syndrome, resulting from 22q11.2 deletion, produces absent or hypoplastic parathyroid glands and thymus, cardiac defects, and facial dysmorphism, occurring in approximately 1 in 4,000 births. Autosomal dominant hypoparathyroidism (ADH) results from activating (gain-of-function) CaSR mutations, which lower the calcium set-point and produce low PTH with hypocalcemia and relative hypercalciuria; this condition may mimic Bartter syndrome type V. HDR syndrome involves hypoparathyroidism, deafness, and renal dysplasia caused by GATA3 mutations. Other rare genetic causes include mitochondrial disorders, Kenny-Caffey syndrome, and Sanjad-Sakati syndrome.

Hypomagnesemia is a critically important and commonly overlooked cause: severe magnesium depletion below 1.0 mg/dL impairs both PTH secretion and induces end-organ PTH resistance, meaning that hypocalcemia cannot be corrected until magnesium is repleted. This occurs commonly in alcoholism, diuretic use, PPI therapy, cisplatin treatment, and gastrointestinal losses. Hungry bone syndrome produces rapid calcium uptake by the skeleton following parathyroidectomy for severe hyperparathyroidism.

PTH-Independent (Normal/High PTH with Hypocalcemia)

In PTH-independent hypocalcemia, PTH is appropriately elevated in response to low calcium, but the calcium remains low due to other mechanisms. Vitamin D deficiency is the most common cause of hypocalcemia globally, resulting from inadequate intake or synthesis, malabsorption (celiac disease, inflammatory bowel disease, bariatric surgery), liver disease (impaired 25-hydroxylation), or chronic kidney disease (impaired 1-alpha-hydroxylation).

Pseudohypoparathyroidism (PHP) represents end-organ resistance to PTH, producing elevated PTH with hypocalcemia and hyperphosphatemia. PHP type 1a, known as Albright hereditary osteodystrophy (AHO), is caused by inactivating mutations of the maternal GNAS1 allele and presents with the characteristic phenotype of short stature, round facies, brachydactyly (particularly short fourth and fifth metacarpals), subcutaneous calcifications, obesity, and cognitive impairment, along with resistance to PTH, TSH, and gonadotropins. PHP type 1b results from GNAS1 methylation defects and produces PTH resistance without the AHO phenotype. Pseudopseudohypoparathyroidism (PPHP) involves paternal GNAS1 mutations that produce the AHO phenotype but with normal calcium and PTH levels, reflecting the genomic imprinting effect.

Additional PTH-independent causes include acute pancreatitis (calcium sequestration by saponification of fat), massive blood transfusion (citrate chelation of ionized calcium), rhabdomyolysis and tumor lysis syndrome (phosphate release binds calcium, leading to calcium-phosphate deposition in tissues), sepsis and critical illness (multifactorial), and medications including bisphosphonates (particularly intravenous zoledronic acid), denosumab, cinacalcet, foscarnet (chelates ionized calcium), and EDTA.

Pseudohypocalcemia

Hypoalbuminemia is the most common cause of low total calcium with normal ionized calcium in hospitalized patients. Ionized calcium should always be checked or total calcium corrected for albumin before making treatment decisions.

<image>A differential diagnosis flowchart for hypocalcemia. Start with confirmed low ionized calcium (or corrected total calcium). First branch: Check PTH level. If PTH low/inappropriately normal → hypoparathyroidism pathway: check surgical history (post-surgical most common), autoimmune markers, magnesium (if low → correct Mg first), genetic evaluation (DiGeorge, ADH), infiltrative workup. If PTH elevated → PTH-independent pathway: check 25(OH)D (if low → vitamin D deficiency; check for malabsorption, CKD), check phosphate (if high → consider pseudohypoparathyroidism, CKD, rhabdomyolysis, tumor lysis; if low/normal → vitamin D deficiency). Include boxes for AHO features in PHP type 1a, and a reminder to always check magnesium in any hypocalcemia evaluation. Use flowchart with decision diamonds and color-coded pathways.</image>

Clinical Features of Hypocalcemia

Neuromuscular

The neuromuscular manifestations of hypocalcemia reflect increased neuronal and muscular excitability resulting from decreased ionized calcium at the cell membrane. Tetany manifests as carpopedal spasm, laryngospasm (which is life-threatening), and generalized muscle cramps. Chvostek sign, elicited by tapping the facial nerve anterior to the ear and observing ipsilateral facial muscle twitching, is present in 10-25% of normocalcemic individuals, limiting its specificity. Trousseau sign is more reliable: inflation of a blood pressure cuff above systolic pressure for 3 minutes induces carpal spasm (main d'accoucheur), characterized by wrist flexion, metacarpophalangeal flexion, interphalangeal extension, and thumb adduction, with a specificity of 94%. Perioral and digital paresthesias are often the earliest symptom, and seizures (generalized tonic-clonic) can occur with severe hypocalcemia.

Cardiac

Hypocalcemia prolongs the QTc interval by delaying ventricular repolarization, creating a risk for torsades de pointes. Heart failure, particularly in children with chronic hypocalcemia, can develop. Refractory hypotension may occur because calcium is a positive inotrope, and its deficiency impairs cardiac contractility.

Chronic Hypocalcemia Features

Long-standing hypocalcemia produces distinctive chronic manifestations. Basal ganglia calcifications, appearing as bilateral calcifications on CT, can produce movement disorders including parkinsonism, dystonia, and chorea, and when extensive are referred to as Fahr syndrome. Posterior subcapsular cataracts are pathognomonic of chronic hypoparathyroidism. Dental abnormalities including enamel hypoplasia, delayed tooth eruption, and dental root abnormalities develop when the onset is in childhood. Dry skin, brittle nails, and coarse hair are common integumentary findings. Papilledema from raised intracranial pressure occurs rarely.

Acute Hypocalcemia Management

Emergency Treatment (Symptomatic Hypocalcemia or Ionized Ca <3.2 mg/dL)

The acute management of symptomatic hypocalcemia is a medical emergency requiring prompt intervention. Intravenous calcium gluconate is the first-line agent: 1-2 ampules (93-186 mg elemental calcium in 10 mL of 10% solution, providing 93 mg per ampule) are diluted in 50-100 mL of D5W or normal saline and infused over 10-20 minutes with continuous cardiac monitoring. This is followed by a continuous infusion of 10 ampules of calcium gluconate in 1 liter of D5W or normal saline, infused at 50 mL/hr and adjusted to maintain ionized calcium above 4.0 mg/dL.

Calcium chloride contains three times more elemental calcium per volume (272 mg per 10 mL) but must be administered through a central line due to the risk of severe tissue necrosis if extravasated. Its use is reserved for cardiac arrest or severe hypotension. Hypomagnesemia must be corrected simultaneously with magnesium sulfate 2 g IV over 20 minutes followed by 1 g/hr continuous infusion, as hypocalcemia will not correct until magnesium is repleted. Monitoring should include ionized calcium every 4-6 hours and cardiac telemetry for QTc surveillance, along with renal function monitoring. An important precaution applies in the setting of digoxin therapy: intravenous calcium can exacerbate digoxin-related arrhythmias.

Transition to Oral Therapy

Oral calcium and calcitriol should be initiated as soon as the patient can take oral medications. Calcium carbonate at 1-3 g of elemental calcium per day in divided doses (or calcium citrate as an alternative) combined with calcitriol 0.25-2 mcg/day in divided doses forms the foundation of oral therapy. Intravenous calcium is tapered as the oral regimen takes effect.

Chronic Hypoparathyroidism Management

Goals of Therapy

The management goals for chronic hypoparathyroidism reflect a balance between maintaining adequate calcium levels and minimizing the complications of treatment. Serum calcium should be maintained in the low-normal range or slightly below normal (8.0-9.0 mg/dL), deliberately avoiding hypercalcemia. Serum phosphate should be kept in the normal range, and the calcium-phosphate product should remain below 55 mg2/dL2. Twenty-four-hour urine calcium should stay below 300 mg/day to avoid hypercalciuria, nephrocalcinosis, and nephrolithiasis. Symptom minimization and quality of life optimization complete the therapeutic goals.

Standard Therapy

Calcium supplementation at 1-3 g of elemental calcium per day in 2-4 divided doses provides the substrate for maintaining serum calcium levels. Active vitamin D in the form of calcitriol, typically dosed at 0.25-2 mcg/day (commonly 0.5-1 mcg twice daily), is necessary because PTH normally drives renal 1-alpha-hydroxylase activity; without PTH, native vitamin D cannot be adequately activated. Alfacalcidol (1-alpha-hydroxyvitamin D), which requires hepatic 25-hydroxylation, serves as an alternative to calcitriol with similar efficacy. Native vitamin D (cholecalciferol or ergocalciferol) should be repleted to achieve 25(OH)D levels above 30 ng/mL, providing substrate for extra-renal 1-alpha-hydroxylase activity. Magnesium supplementation is provided when levels are low, using magnesium oxide 400-800 mg/day or magnesium citrate, though gastrointestinal side effects can be limiting. Thiazide diuretics (hydrochlorothiazide 25-50 mg/day) serve as a useful adjunct by reducing urinary calcium excretion when hypercalciuria persists despite dose optimization.

Monitoring

Serum calcium, phosphate, magnesium, and creatinine should be measured every 3-6 months. Twenty-four-hour urine calcium should be assessed annually, targeting less than 300 mg/day (ideally less than 250 mg/day). Renal ultrasound every 1-2 years screens for nephrocalcinosis and nephrolithiasis. Periodic ophthalmologic examinations monitor for cataract development. If the calcium-phosphate product is persistently elevated, calcium doses should be reduced and/or a low-phosphate diet instituted.

Complications of Long-Term Treatment

Hypercalciuria is the leading complication of conventional therapy, with nephrocalcinosis, nephrolithiasis, and progressive CKD developing in up to 30-50% of patients over decades. Ectopic calcifications, particularly in the basal ganglia (especially when the calcium-phosphate product is elevated), kidneys, and vasculature, represent another significant concern. Impaired quality of life, manifesting as "brain fog," fatigue, anxiety, and depression, is reported in 50-80% of hypoparathyroidism patients despite apparently adequate calcium levels. This discordance between biochemical adequacy and clinical well-being reflects a fundamental limitation of conventional therapy: it replaces calcium but does not restore the full spectrum of physiologic PTH actions, including renal calcium conservation, calcitriol production, and bone turnover regulation.

<image>A comparison diagram showing conventional vs PTH replacement therapy for hypoparathyroidism. Left side (Conventional therapy): show calcium + calcitriol supplementation with drawbacks illustrated - persistent hypercalciuria shown as calcium crystals in kidney, need for high-dose calcium supplements shown as multiple large pills, episodes of both hypo and hypercalcemia shown as unstable calcium graph, and poor quality of life. Right side (PTH replacement - TransCon PTH/Natpara): show PTH pump/injection restoring physiologic calcium regulation - reduced calcitriol dose needed, reduced calcium supplements needed, lower urine calcium, more stable serum calcium graph, improved bone turnover markers. Include the mechanism: PTH activates renal calcium reabsorption, stimulates 1-alpha-hydroxylase, and normalizes bone turnover. Use split-panel comparison format.</image>

PTH Replacement Therapy

Recombinant PTH(1-84) (Natpara/rhPTH)

Recombinant PTH(1-84) received FDA approval in 2015 for chronic hypoparathyroidism inadequately controlled on conventional therapy. Dosed at 50-100 mcg subcutaneously daily with titration based on calcium, urine calcium, and calcitriol dose, it reduces calcium supplement and calcitriol requirements by approximately 50%, decreases urinary calcium excretion, provides more stable serum calcium levels, and normalizes bone turnover on histomorphometry. A black box warning exists for osteosarcoma risk based on rodent studies involving 2-year continuous exposure in Fischer 344 rats, with monitoring via imaging recommended and contraindications in patients at increased baseline osteosarcoma risk (open epiphyses, Paget disease, prior radiation, unexplained alkaline phosphatase elevation). A voluntary recall occurred in 2019 due to rubber particles in the cartridge, with subsequent return to market with a new device. Limited availability and high cost (exceeding $200,000 per year) restrict access.

TransCon PTH (Palopegteriparatide)

Palopegteriparatide represents the next generation of PTH replacement, employing a long-acting prodrug of PTH(1-34) that achieves sustained PTH release through TransCon linker technology. It received FDA approval in 2024 for chronic hypoparathyroidism. Dosed at 18-30 mcg subcutaneously daily, the PaTHway trial demonstrated normalization of serum calcium in 79% of patients (versus 5% with placebo) while reducing or eliminating calcium and calcitriol supplements, reducing urinary calcium excretion, and improving quality of life. The more physiologic sustained PTH levels achieved throughout the day distinguish it from earlier PTH preparations. No osteosarcoma signal has been observed to date, likely reflecting a different exposure profile. This agent is likely to become the new standard of care for hypoparathyroidism management.

Autoimmune Polyglandular Syndrome Type 1 (APS-1/APECED)

Genetics and Pathophysiology

APS-1 results from autosomal recessive mutations in the AIRE gene, which encodes a transcriptional regulator essential for central immune tolerance in the thymus. Loss of AIRE function impairs the deletion of autoreactive T cells during thymic education, leading to multi-organ autoimmunity.

Classic Triad

The classic triad consists of chronic mucocutaneous candidiasis (usually the first manifestation, appearing in childhood), hypoparathyroidism (typically the second manifestation, occurring in childhood or adolescence), and adrenal insufficiency (Addison disease, often the third, presenting in adolescence or young adulthood). Two of three features are required for diagnosis, or one of three if a sibling has confirmed APS-1.

Additional Manifestations

The spectrum of APS-1 extends well beyond the classic triad to include type 1 diabetes, autoimmune hepatitis, pernicious anemia, alopecia, vitiligo, gonadal failure, ectodermal dystrophy, and keratopathy. Characteristic autoantibodies include anti-IFN-omega and anti-IFN-alpha2 (highly specific, present in over 95% of patients), anti-IL-17A and anti-IL-22 (associated with candidiasis), anti-CaSR and anti-NALP5 (associated with hypoparathyroidism), and anti-21-hydroxylase (associated with adrenal insufficiency).

Key Clinical Pearls

• Hypomagnesemia is the most commonly overlooked cause of refractory hypocalcemia; severe Mg deficiency (<1.0 mg/dL) impairs both PTH secretion and peripheral PTH action; always check and correct magnesium before attributing hypocalcemia to other causes
• Post-thyroidectomy hypocalcemia is the most common cause of hypoparathyroidism; transient in 70-80% of cases, but permanent if persisting >6 months; intraoperative PTH decline and immediate post-op PTH <10 pg/mL predict permanent hypoparathyroidism
• In chronic hypoparathyroidism, the biggest treatment challenge is hypercalciuria (not hypocalcemia); conventional therapy with calcium + calcitriol promotes renal calcium excretion without the PTH-dependent renal calcium reabsorption → nephrolithiasis and nephrocalcinosis in 30-50% of patients
• PTH replacement therapy (palopegteriparatide/TransCon PTH) represents a paradigm shift from treating the consequence (low calcium) to replacing the missing hormone (PTH); it reduces supplement burden and urinary calcium while improving quality of life
• Activating CaSR mutations (autosomal dominant hypoparathyroidism) cause a biochemical picture identical to hypoparathyroidism but with inappropriately high urinary calcium; aggressive calcium/calcitriol treatment worsens hypercalciuria and renal complications; aim for lower serum calcium targets
• APS-1 (APECED) should be suspected in any child with unexplained hypoparathyroidism, mucocutaneous candidiasis, or adrenal insufficiency; anti-IFN-omega antibodies are highly specific and diagnostic

References

1. Bollerslev J, et al. "European Society of Endocrinology Clinical Guideline: Treatment of Chronic Hypoparathyroidism in Adults." Eur J Endocrinol. 2015;173(2):G1-G20.
2. Khan AA, et al. "Standards of Care for Hypoparathyroidism in Adults: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2024 (updated).
3. Mannstadt M, et al. "Hypoparathyroidism." Nat Rev Dis Primers. 2017;3:17055.
4. Sikjaer T, et al. "PTH(1-84) Replacement Therapy in Hypoparathyroidism: A Randomized Controlled Trial on Pharmacokinetic and Dynamic Effects." J Bone Miner Res. 2013;28(10):2232-2243.
5. Khan AA, et al. "Palopegteriparatide (TransCon PTH) for Hypoparathyroidism (PaTHway)." N Engl J Med. 2023;389(24):2246-2257.

Read this lecture as Markdown